Table 1 Associations of S100β expression in ER-positive endocrine-treated breast cancer tissue (n = 536) and serum (n = 187) with clinicopathologic variables and disease recurrence using Fisher’s exact test. Associations between disease-free survival times and individual variables using Wilcoxon. Median age for patient TMA and serum samples was 56.12 and 51.15 years respectively, and median follow-up time was 76.84 and 66.1 months respectively
From: S100β as a serum marker in endocrine resistant breast cancer
Patient TMA | Patient serum samples | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Variable | Total n | S100β + ve | S100β –ve | p Fisher | p Wilcoxon | Total n | S100β ≥0.13 μg/L | S100β <0.13 μg/L | p Fisher | p Wilcoxon | |
S100β | 536 | 34.7% | 65.30% | <0.0001 | 187 | 10.16% | 89.84% | 0.0011 | |||
Age | |||||||||||
≥55 | 303 | 56.45% | 56.57% | 1.0 | 0.4 | 75 | 47.37% | 39.29% | 0.622 | 0.4 | |
<55 | 233 | 43.55% | 43.43% | 112 | 52.63% | 60.71% | |||||
PR | |||||||||||
+ ve | 321 | 65.50% | 66.56% | 0.841 | 0.4 | 159 | 57.89% | 88.62% | 0.002 | 0.8 | |
− ve | 164 | 34.50% | 33.44% | 27 | 42.11% | 11.38% | |||||
HER2 | |||||||||||
+ ve | 85 | 18.93% | 17.10% | 0.619 | 0.2 | 26 | 15.79% | 13.69% | 0.732 | 0.7 | |
− ve | 394 | 81.07% | 82.90% | 161 | 84.21% | 86.31% | |||||
Nodal status | |||||||||||
+ ve | 273 | 49.46% | 52.62% | 0.524 | <0.0001 | 99 | 53.33% | 58.71% | 0.786 | 0.05 | |
− ve | 257 | 50.54% | 47.38% | 71 | 46.67% | 41.29% | |||||
Grade | |||||||||||
≥ Grade 3 | 147 | 34.88% | 27.10% | 0.079 | 0.03 | 52 | 31.58% | 27.38% | 0.788 | 0.2 | |
< Grade 3 | 346 | 65.12% | 72.90% | 135 | 68.42% | 72.62% | |||||
Tumor size | |||||||||||
≥20 mm | 369 | 70.97% | 67.71% | 0.493 | 0.004 | 137 | 94.44% | 86.33% | 0.473 | 0.5 | |
<20 mm | 167 | 29.03% | 32.29% | 20 | 5.56% | 13.67% | |||||
Hormonal therapy | |||||||||||
Tamoxifen | 459 | 83.87% | 86.57% | 0.438 | 0.4 | 110 | 42.11% | 60.71% | 0.143 | 0.7 | |
AI | 126 | 25.81% | 22.29% | 0.392 | 0.5 | 108 | 73.68% | 55.95% | 0.152 | 0.2 | |
Other therapy | |||||||||||
Chemotherapy | 166 | 34.64% | 31.23% | 0.431 | 0.1 | 119 | 61.11% | 66.26% | 0.794 | 0.2 | |
Radiation | 296 | 62.16% | 52.01% | 0.028 | 0.5 | 121 | 70.59% | 74.66% | 0.771 | 0.01 | |
Herceptin | 23 | 6.49% | 3.14% | 0.077 | 0.06 | 10 | 5.26% | 5.36% | 1.00 | 0.87 | |
Recurrence | |||||||||||
+ ve | 156 | 40.32% | 23.14% | <0.0001 | 33 | 47.37% | 14.29% | 0.002 | |||
− ve | 380 | 59.68% | 76.86% | 154 | 52.63% | 85.71% | |||||
HOXC11 | |||||||||||
+ ve | 74 | 83.93% | 18.49% | <0.0001 | <0.0001 | ||||||
− ve | 128 | 16.07% | 81.51% | ||||||||